| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IGFBP7 |
| Uniprot No | Q16270 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-282aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSSSSDTCGPCEPASCPPLPPLGCLLGET RDACGCCPMCARGEGEPCGGGGAGRGYCAPGMECVKSRKRRKGKAGAAAG GPGVSGVCVCKSRYPVCGSDGTTYPSGCQLRAASQRAESRGEKAITQVSK GTCEQGPSIVTPPKDIWNVTGAQVYLSCEVIGIPTPVLIWNKVKRGHYGV QRTELLPGDRDNLAIQTRGGPEKHEVTGWVLVSPLSKEDAGEYECHASNS QGQASASAKITVVDALHEIPVKKGEGAEL |
| 预测分子量 | 29 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IGFBP7重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**：*IGFBP7 binds to the IGF-1 receptor and blocks its activation by insulin-like growth factors*
**作者**：Oh Y. et al.
**摘要**：研究揭示重组IGFBP7蛋白通过直接结合IGF-1受体，抑制IGF-1和IGF-2的活性，调控细胞增殖和代谢，提示其在肿瘤治疗中的潜在作用。
2. **文献名称**：*Recombinant IGFBP7 inhibits angiogenesis and tumor growth in a preclinical model of melanoma*
**作者**：Wajapeyee N. et al.
**摘要**：通过黑色素瘤模型实验，证明重组IGFBP7蛋白通过抑制VEGF信号通路和诱导内皮细胞凋亡，显著抑制肿瘤血管生成及生长。
3. **文献名称**：*Structural and functional characterization of recombinant human IGFBP7: Insights into its role in senescence*
**作者**：Kim H. et al.
**摘要**：解析重组人IGFBP7的晶体结构，发现其独特的结构域与细胞衰老相关蛋白相互作用，证实其通过p53通路促进细胞衰老和抑制肿瘤增殖。
4. **文献名称**：*IGFBP7 as a potential biomarker in heart failure: Recombinant protein-based clinical validation*
**作者**：Chen J. et al.
**摘要**：临床研究表明，血液中IGFBP7重组蛋白水平与心力衰竭严重程度相关，提示其作为新型生物标志物用于疾病诊断和预后评估。
以上文献涵盖IGFBP7重组蛋白在肿瘤抑制、血管生成调控、结构功能解析及临床诊断中的应用。
**Background of IGFBP7 Recombinant Protein**
Insulin-like growth factor-binding protein 7 (IGFBP7), also known as IGFBP-rP1 or MAC25. is a secreted glycoprotein belonging to the IGFBP superfamily. Unlike canonical IGFBPs that primarily regulate IGF bioavailability, IGFBP7 exhibits low affinity for IGFs but interacts with other signaling molecules, including insulin receptors, integrins, and TGF-β pathway components. It plays multifaceted roles in cellular processes such as senescence, apoptosis, angiogenesis, and extracellular matrix remodeling. Structurally, IGFBP7 contains an N-terminal IGF-binding domain and a C-terminal thyroglobulin-type-1 domain, enabling diverse molecular interactions.
IGFBP7 is implicated in both physiological and pathological contexts. In cancer, it acts as a tumor suppressor by inducing cell cycle arrest or apoptosis in certain malignancies (e.g., breast and liver cancers) but may promote metastasis in others (e.g., melanoma) through pro-angiogenic or stromal remodeling effects. Its dysregulation is also linked to metabolic disorders, fibrotic diseases, and age-related conditions.
Recombinant IGFBP7 protein is produced using expression systems like *E. coli* or mammalian cells, ensuring post-translational modifications critical for functionality. Purified via affinity chromatography, it serves as a tool for studying IGF-independent pathways, drug discovery, or therapeutic applications. For instance, recombinant IGFBP7 has been explored for anti-angiogenic therapy or as a biomarker in cancer diagnostics. Emerging research highlights its potential in modulating immune responses and tissue repair, underscoring its versatility as a therapeutic target.
Overall, IGFBP7 recombinant protein remains a focal point in unraveling complex disease mechanisms and developing targeted interventions.
×
